PMID- 24923635
OWN - NLM
STAT- MEDLINE
DCOM- 20141228
LR  - 20140701
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 32
IP  - 33
DP  - 2014 Jul 16
TI  - Lessons learned during the development and transfer of technology related to a 
      new Hib conjugate vaccine to emerging vaccine manufacturers.
PG  - 4124-30
LID - S0264-410X(14)00679-3 [pii]
LID - 10.1016/j.vaccine.2014.05.023 [doi]
AB  - The incidence of Haemophilus Influenzae type b (Hib) disease in developed 
      countries has decreased since the introduction of Hib conjugate vaccines in their 
      National Immunization Programs (NIP). In countries where Hib vaccination is not 
      applied routinely, due to limited availability and high cost of the vaccines, 
      invasive Hib disease is still a cause of mortality. Through the development of a 
      production process for a Hib conjugate vaccine and related quality control tests 
      and the transfer of this technology to emerging vaccine manufacturers in 
      developing countries, a substantial contribution was made to the availability and 
      affordability of Hib conjugate vaccines in these countries. Technology transfer 
      is considered to be one of the fastest ways to get access to the technology 
      needed for the production of vaccines. The first Hib conjugate vaccine based on 
      the transferred technology was licensed in 2007, since then more Hib vaccines 
      based on this technology were licensed. This paper describes the successful 
      development and transfer of Hib conjugate vaccine technology to vaccine 
      manufacturers in India, China and Indonesia. By describing the lessons learned in 
      this process, it is hoped that other technology transfer projects can benefit 
      from the knowledge and experience gained.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Hamidi, A
AU  - Hamidi A
AD  - Institute for Translational Vaccinology, Bilthoven, The Netherlands. Electronic 
      address: ahd.hamidi@intravacc.nl.
FAU - Boog, C
AU  - Boog C
AD  - Institute for Translational Vaccinology, Bilthoven, The Netherlands.
FAU - Jadhav, S
AU  - Jadhav S
AD  - Serum Institute of India Limited, Pune, India.
FAU - Kreeftenberg, H
AU  - Kreeftenberg H
AD  - Institute for Translational Vaccinology, Bilthoven, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140609
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Haemophilus Vaccines)
RN  - 0 (Haemophilus influenzae type b polysaccharide vaccine)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
MH  - Bacterial Capsules
MH  - China
MH  - Developing Countries
MH  - Haemophilus Infections/*prevention & control
MH  - Haemophilus Vaccines/*economics
MH  - Haemophilus influenzae type b
MH  - Humans
MH  - India
MH  - Indonesia
MH  - Meningitis, Haemophilus/prevention & control
MH  - *Technology Transfer
MH  - Technology, Pharmaceutical
MH  - Vaccines, Conjugate/economics
OTO - NOTNLM
OT  - Haemophilus Influenzae type b
OT  - Lessons learned
OT  - Technology transfer developing countries vaccine manufacturers
OT  - Vaccine
EDAT- 2014/06/14 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/06/14 06:00
PHST- 2014/02/24 00:00 [received]
PHST- 2014/04/28 00:00 [revised]
PHST- 2014/05/01 00:00 [accepted]
PHST- 2014/06/14 06:00 [entrez]
PHST- 2014/06/14 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - S0264-410X(14)00679-3 [pii]
AID - 10.1016/j.vaccine.2014.05.023 [doi]
PST - ppublish
SO  - Vaccine. 2014 Jul 16;32(33):4124-30. doi: 10.1016/j.vaccine.2014.05.023. Epub 
      2014 Jun 9.